Clinical trials: Lipid Profiles
Hypertension, Hypercholesterolemia
Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients
The primary objective is to investigate the safety of Caduet (2.5 mg/5 mg, 2.5 mg/10 mg, 5 mg/5 mg or 5 mg/10 mg as dose of Amlodipine/Atorvastatin) during 52 weeks treatment period in Japanese patients with both of hypertension…
- Conditions
- Hypertension, Hypercholesterolemia, Angina Pectoris
- Trial name
- NCT01190007
- Testing
- Caduet
- Where
- 20 sites in Japan
- Volunteers
- 159 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
HIV, Hyperlipidemia
Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
The success of combination antiretroviral therapy heralded a revolution in the treatment of HIV in the mid-1990s. However, severe treatment-associated side effects have been observed including diabetes and increased cholesterol…
- Conditions
- HIV, Hyperlipidemia, Hypertriglyceridemia, HIV Infections
- Trial name
- NCT00887653
- Testing
- raltegravir
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- The Miriam Hospital
Body Composition, Performance Measures
Effects of Shroom Tech Sport Supplementation and Concurrent Training
This study will examine how the supplement Shroom Tech Sport (STS) affects body composition and different performance and health measures over the course of 12 weeks.
- Conditions
- Body Composition, Performance Measures, Hormone Profiles, Blood Lipid Profiles
- Trial name
- NCT02383017
- Testing
- Shroom Tech Sport
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Florida State University
Type 2 Diabetes, Insulin Resistance
Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance
The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in…
- Conditions
- Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome
- Trial name
- NCT00443755
- Testing
- metformin, pioglitazone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Dyslipidemias, Hypercholesterolemia
Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204)
The current study is proposed to investigate the pattern of dyslipidemia and of lipid treatment practices in patients in India experiencing their first acute cardiovascular event and the extent of residual dyslipidemia after 12…
- Conditions
- Dyslipidemias, Hypercholesterolemia, Hypertriglyceridemia, High LDL-C
- Trial name
- REMAINS (NCT01245738)
- Volunteers
- 635 people
- Sponsor
- Merck Sharp & Dohme LLC
Oxidative Stress, Dyslipidemias
Effects of Octacosanol During Taekwondo Training
Taekwondo players undergo rapid reductions of body weight prior to their competition in order to gain a size advantage over the opponent.
- Trial name
- NCT03557476
- Testing
- Octacosanol
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Kosin University
HIV, Dyslipidemia
Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir
Dyslipidemia as a risk factor for cardiovascular disease (CVD) is an increasing problem in HIV-infected patients who are on antiretroviral therapy especially protease inhibitors including atazanavir.
- Trial name
- NCT02442700
- Testing
- pitavastatin
- Volunteers
- 24 people
- Sponsor
- Ramathibodi Hospital
Type 2 Diabetes, Hyperlipidemia
Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin
A 16 week open-label study with subjects receiving background metformin monotherapy. 150 subjects randomized 1:1:1 to receive 1 of the following: open-label colesevelam HCl, open label rosiglitazone, or open-label sitagliptin.
- Trial name
- NCT00484419
- Testing
- Colesevelam HCl, rosiglitazone maleate, sitagliptin phosphate
- Where
- 20 sites in United States
- Volunteers
- 169 people
- Sponsor
- Daiichi Sankyo